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Abstract 
Imidazoline receptors (IRs) have been recognized as promising targets in the treatment of 
numerous diseases, and moxonidine and rilmenidine, agonists of I1-IRs are widely used as 
antihypertensive agents. Some evidence suggests that IR ligands may induce anti-inflammatory 
effects acting on I1-IRs or other molecular targets, which could be beneficial in patients with 
inflammatory bowel disease (IBD). On the other hand, several IR ligands may stimulate also 
alpha2-adrenoceptors, which was earlier shown to inhibit, but in more recent studies to rather 
aggravate colitis. Hence, this study aimed to analyse for the first time the effect of various I1-
IR ligands on intestinal inflammation. Colitis was induced in C57BL/6 mice by adding dextran 
sulfate sodium (DSS) to the drinking water for 7 days. Mice were treated daily with different 
IR ligands; moxonidine and rilmenidine (I1-IR agonists), AGN 192403 (highly selective I1-IR 
ligand, putative antagonist), efaroxan (I1-IR antagonist), as well as with the endogenous IR 
agonists agmatine and harmane. It was found that moxonidine and rilmenidine at clinically 
relevant doses, similarly to the other IR ligands, do not have a significant impact on the 
macroscopic and histological signs of DSS-evoked inflammation. Likewise, colonic 
myeloperoxidase and serum interleukin-6 levels remained unchanged in response to these 
agents. Thus, our study demonstrates that imidazoline ligands do not influence significantly the 
severity of DSS-colitis in mice and suggest that they probably neither affect the course of IBD 
in humans. However, the translational value of these findings needs to be verified with other 
experimental colitis models and human studies. 
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1. Introduction 
The discovery of non-adrenergic binding sites that may mediate the hypotensive effect 
of clonidine and other imidazoline derivatives can be dated back to the 1980s (Bousquet et al. 
1984). Since then pharmacological studies have revealed the existence of at least three distinct 
types of imidazoline receptors (IRs), named I1-, I2- and non-I1-non-I2 or I3-IRs, and suggested 
that they may be promising targets in the treatment of numerous diseases, including 
hypertension, diabetes, depression and chronic pain (for reviews see e.g. Bousquet et al. 2003; 
Eglen et al. 1998; Head and Mayorov 2006; Li and Zhang 2011). Research on IRs has led to 
the development of moxonidine and rilmenidine, which have higher affinity for I1-IRs than for 
alpha2-adrenoceptors and used world-wide as antihypertensive agents (Edwards et al. 2012; 
Verbeuren et al. 1990). Moreover, it has also led to an intensive search for their endogenous 
ligands, and various substances were proposed as likely candidates, such as clonidine displacing 
substance (CDS) (Atlas and Burstein 1984), agmatine (Li et al. 1994), harmane (Parker et al. 
2004) and imidazole-acetic acid ribotide (Prell et al. 2004). 
Concerning the gastrointestinal (GI) tract, radioligand binding studies provided 
evidence for the presence of IRs in the stomach and intestines of different mammals (Houi et 
al. 1987; Molderings et al. 1998; Senard et al. 1990; Wikberg et al. 1991). CDS and agmatine 
were also identified in the GI tract (Meeley et al. 1992; Raasch et al. 1995), in fact, the highest 
concentrations of agmatine were measured in the stomach and intestines among all tissues in 
the rat (Raasch et al. 1995). Because these data suggest an important role for IRs and their 
ligands in the gut, in the last two decades a number of studies were conducted to assess the GI 
effects of various non-selective and highly selective I1- and I2-IR ligands, sometimes leading to 
conflicting results (e.g. Colucci et al. 1998; Glavin and Smyth 1995; Kaliszan et al. 2006; Liu 
and Coupar 1997; Zádori et al. 2013). 
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Some sporadic evidence suggests that imidazoline drugs may induce anti-inflammatory 
effects as well. For example, clonidine and its structural analog (Holsapple et al. 1984; Kulkarni 
et al. 1986) as well as rilmenidine (Gyires et al. 2009) inhibited acute paw edema in rats, which 
was likely mediated by alpha2-adrenoceptors (Gyires et al. 2009; Kulkarni et al. 1986). 
Moxonidine reduced the level of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-
α) in the serum of hypertensive postmenopausal women (Pöyhönen-Alho et al. 2008). 
Furthermore, some data suggest that I1-IR ligands may interfere with sphingosine 1-phosphate 
(S1P) receptor signaling (Molderings et al. 2007a, b). Because S1P receptors have pivotal role 
in the regulation of immune cell trafficking (reviewed e.g. by Aoki et al. 2016; Chi 2011; Cyster 
and Schwab 2012), it can be speculated that I1-IR ligands may have immunomodulatory 
properties, similarly to the S1P receptor modulator FTY720, which has potent anti-
inflammatory effect in various clinical and preclinical inflammatory conditions, including 
dextran sulfate sodium (DSS)- and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-evoked murine 
colitis (Daniel et al. 2007; Deguchi et al. 2006). In short, these data suggest that imidazoline 
drugs, such as moxonidine and rilmenidine, may have beneficial (and yet unrecognized) effects 
in patients with inflammatory diseases, including colitis. 
On the other hand, many IR ligands can bind to and activate alpha2-adrenoceptors as 
well (Szabó 2002). This might contribute to their anti-inflammatory effect in some types of 
inflammation (see above), and according to earlier studies may improve the symptoms of 
patients with inflammatory bowel disease (IBD) as well (Furlan et al. 2006; Lechin et al. 1985). 
However, more recent findings suggest that alpha2-adrenoceptors are overactive in the acute 
phase of colitis and contribute to a pro-inflammatory mileu, and stimulation of these receptors 
may exacerbate, whereas their inhibition ameliorates colitis (Bai et al. 2009, 2015; Zádori et al. 
2016). These findings raise concern that antihypertensive agents acting at I1-IRs and alpha2-
adrenoceptors may have detrimental effect in IBD patients. 
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Because to date (to our best knowledge) no study has been conducted to assess the effect 
of imidazoline drugs on intestinal inflammation, we aimed to analyse, whether and how 
moxonidine, rilmenidine and other I1-IR ligands influence the course of chemically induced 
colitis in mice. 
  
 6 
2. Methods & Materials 
2.1. Experimental animals 
Experiments were carried out in 8 weeks old female C57BL/6 mice (National Institute 
of Oncology, Budapest, Hungary). Animals were housed in a temperature (222C)- and 
humidity-controlled room at a 12-h light/dark cycle under conditions of animal housing and 
experimentation according to ethical guidelines issued by the Ethical Board of Semmelweis 
University, based on EC Directive 86/609/EEC. Food and water were available ad libitum. 
All procedures conformed to the European Convention for the protection of vertebrate 
animals used for experimental and other scientific purposes, and all efforts were made to 
minimize the suffering of animals. Number of animals in each experimental group was reduced 
to the minimum required for a statistical analysis and preemptive euthanasia was performed if 
mice became moribund. The experiments were approved by the National Scientific Ethical 
Committee on Animal Experimentation and permitted by the government (Food Chain Safety 
and Animal Health Directorate of the Central Agricultural Office (PEI/001/1493-4/2015)). 
2.2. Induction of colitis 
Colitis was induced by adding DSS (2.5 %, molecular weight: 35000-55 000 Da; TdB 
Consultancy, Uppsala, Sweden) (Jädert et al. 2014) to the drinking water (tap water) for 3, 5 or 
7 days (see Section 2.3). The DSS-containing drinking water was made up fresh every second 
day to avoid bacterial contamination, and the consumption of water and food was monitored in 
all groups. Body weight was measured daily during the course of the treatment. The 
development of colitis was evaluated by recording the disease activity index (DAI) covering 
the general condition of animals (0, normal; 1, weak, sick in appearance; 2, moribund), stool 
consistency (0, normal; 1, normal/soft; 2, soft/watery; 3, watery diarrhea) and presence of faecal 
blood (0, no trace of blood; 1, traces of blood on the stool; 2, bloody stool; 3, gross bleeding). 
The scores in each category were summed up, resulting in a total score between 0 and 8. At day 
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7-10 after colitis induction mice were sacrificed by decapitation and their whole colons were 
removed. The reduction of colon length was used as another parameter to assess colonic 
inflammation (Jädert et al. 2014). Care was taken not to stretch the colon. The length was 
expressed as percent of length in the control group. Afterwards full-thickness pieces of the distal 
colon were excised for further analysis. Serum samples were also collected and stored at -80°C 
until assayed. 
2.3. Study design 
Study 1. In order to characterize the effect of 2.5 % DSS, 48 mice were randomly 
allocated into 4 groups. Animals in the 1st group (control, n=12) drank normal tap water for 10 
days. Animals in the 2nd (n=6) and 3rd (n=12) groups received 2.5 % DSS for 3 and 5 days, 
respectively, and were sacrificed on day 10, like the control group (DSS 3d and DSS 5d). 
Animals in the 4th group received 2.5 % DSS for 7 days (DSS 7d, n=18), but after that they 
were further divided into 3 subgroups (n=6 in each group) and sacrificed at different time points 
(on days 7, 9 and 10). 
Study 2. In 4 separate experiments the effects of moxonidine and rilmenidine (I1-IR 
agonists) as well as of AGN 192403 (highly selective I1-IR ligand, putative antagonist) and 
efaroxan (I1-IR antagonist) (Dardonville and Rozas 2004) on the development of colitis were 
analysed. The chemical names of these drugs and their affinities for IRs and alpha2-
adrenoceptors are shown in Table 1. In these experiments mice were randomly divided into 5-
6 groups (6 mice in each group). The 1st and 2nd groups drank normal tap water and were 
treated either with saline (SAL) or with moxonidine (MOX, 0.1 mg/kg), rilmenidine (RIL, 0.1 
mg/kg), AGN 192403 (AGN, 0.1 mg/kg) or efaroxan (EFA, 1 mg/kg). The other groups drank 
2.5 % DSS for 7 days and were treated with either saline (DSS+SAL) or with different doses 
of the I1-IR ligands (moxonidine and rilmenidine: 0.01, 0.1 and 1 mg/kg; AGN 192403: 0.1, 1 
and 10 mg/kg; efaroxan: 0.1 and 1 mg/kg). Saline and all test compounds were injected 
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intraperitoneally (i.p.), once daily, in a volume of 0.1 ml/10 g. The applied doses were selected 
based on literature data (Cobos-Puc et al. 2009; Gyires et al. 2009; Zeidan et al. 2007; Zhu et 
al. 1999). All animals were sacrificed at day 9 after colitis induction. 
Study 3. In this study the effects of two commercially available endogenous IR agonists 
(agmatine and harmane, Table 1) on the course of DSS-induced colitis were assessed. In 2 
experiments 36 and 30 mice were randomly allocated into 6 and 5 groups, respectively (6 
mice/group). The 1st and 2nd groups in each experiment drank normal tap water and were 
treated either with vehicle (VEH; saline in case of agmatine (SAL) or 1.7 % acetic acid in case 
of harmane), or with agmatine (AGM, 30 mg/kg) or harmane (HAR, 2.5 mg/kg). The other 
groups drank 2.5 % DSS for 7 days and were treated with either vehicle or with different doses 
of the endogenous IR ligands (agmatine: 10, 30 and 100 mg/kg; harmane: 2.5 and 10 mg/kg). 
Agmatine and saline were injected i.p., whereas harmane and 1.7 % acetic acid were injected 
intragastrically by an oral gavage, in a volume of 0.1 ml/10 g, once daily. The applied doses 
were selected based on literature data (Aricioglu et al. 2003; Zádori et al. 2014; Zeidan et al. 
2007). Animals were sacrificed at day 9 after colitis induction, as in the previous study. 
Study 4. In this study we analysed whether the effect of IR ligands can be enhanced by 
injecting them more frequently. 36 mice were divided into 6 groups (6 mice/group). The 1st 
group drank normal tap water and was treated with saline (SAL). The other 5 groups drank 
2.5 % DSS for 7 days and were treated either with saline (DSS+SAL) or with moxonidine 
(MOX, 0.1 mg/kg), rilmenidine (RIL, 0.1 mg/kg), AGN 192403 (AGN, 0.1 mg/kg) or efaroxan 
(EFA, 1 mg/kg). Drugs and saline were injected i.p., twice daily (at 9 am and 6 pm). Animals 
were sacrificed at day 9 after colitis induction. 
2.4. Histological analysis 
The distal colon samples were fixed in 40 mg/ml buffered formaldehyde, embedded in 
paraffin, sectioned (5 µm), and stained with haematoxylin and eosin. Digital micrographs were 
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taken by an Olympus BX51 microscope and Olympus DP50 camera. The sections were taken 
randomly from the distal colon, and histological injury was assessed in qualitative terms. 
2.5. Measurement of colonic myeloperoxidase levels 
The tissue levels of myeloperoxidase (MPO) were determined to quantify inflammation-
associated infiltration of neutrophils into the tissue. Full-thickness pieces of the distal colon 
were excised, shock-frozen in liquid nitrogen and stored at -80°C until assay. After weighing, 
tissues were homogenized in lysis buffer containing 200 mM NaCl, 5 mM EDTA, 10 mM tris, 
10% glycerine and 1 mM PMSF (pH 7.4), supplemented with a protease inhibitor cocktail 
(cOmplete ULTRA Tablets, Roche, Basel, Switzerland). The MPO content of the supernatant 
was measured with an enzyme-linked immunosorbent assay (ELISA) kit specific for the mouse 
protein (Hycult Biotechnology, Uden, the Netherlands). Protein concentration of the 
homogenates was determined by bicinchoninic acid (BCA) assay kit (Thermo Scientific Pierce 
Protein Research Products, Rockford, USA) with bovine serum albumin as a standard, and the 
level of MPO was expressed as ng/mg of total protein. 
2.6. Measurement of interleukin-6 levels in serum 
Blood samples were allowed to clot at room temperature for 30 min before 
centrifugation (2000×g, 4°C, 10 min), then sera were collected and stored at -80°C until assay. 
The interleukin-6 (IL-6) content of sera was determined with ELISA kit specific for the mouse 
protein (Invitrogen, Thermo Fisher Scientific, Waltham, USA) according the manufacturer’s 
instructions. Protein concentration of samples was determined by BCA assay with bovine serum 
albumin as a standard, and the level of IL-6 was expressed as pg/mg of total protein. 
2.7. Materials 
Moxonidine, rilmenidine, AGN 192403 and CYM 5442 (2-(4-(5-(3,4-Diethoxyphenyl)-
1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino) ethanol) were ordered from Tocris 
Bioscience (Bristol, UK). Efaroxan, agmatine, and harmane, as well as all other chemicals, 
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unless otherwise stated, were purchased from Sigma (St Louis, MO, USA). For chemical names 
of IR ligands see Table 1. 
2.8. Statistical analysis 
Data are expressed as means ± S.E.M. Statistical analysis of the data was performed 
with one-way ANOVA followed by Holm-Sidak post hoc test. Two-way repeated measures 
ANOVA and Friedman test were employed to compare the time course of weight losses and 
disease activity indices, respectively, between different groups. Kaplan-Meier test was used for 
analysis of survival rates. A probability of p<0.05 was considered statistically significant. 
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3. Results 
3.1. Characterization of the effect of 2.5 % DSS 
Because the severity and pathological features of DSS-induced colitis depend on 
multiple factors, including the duration of DSS exposure (reviewed e.g. by Perse and Cerar 
2012), in the first step we tested different protocols and applied 2.5 % DSS for 3 different time 
intervals (3, 5 and 7 days). As Fig. 1 shows, DSS induced a typical inflammatory response in 
all groups, characterized by diarrhea, blood in the faeces, weight loss and colon shortening, and 
the severity of these symptoms heavily depended on the duration of DSS exposure. Namely, a 
3-day exposure to DSS followed by 7 days recovery induced only a mild inflammatory 
response, which peaked at day 6 and resolved almost completely, whereas a 5-day DSS 
exposure (followed by 5 days recovery) and a 7-day DSS exposure induced modest and severe 
colonic inflammations, respectively. Animals in the last group (exposed to DSS for 7 days) 
were sacrificed at 3 different time points (immediately after DSS exposure, and on days 9 and 
10), which allowed us to analyse the time course of colon shortening (Fig. 1C). 
Since we hypothesized that IR ligands may have primarily beneficial effect on colonic 
inflammation, we aimed at inducing moderate to severe colitis and chose the protocol with a 7-
day DSS exposure for subsequent studies. Considering the low (60 %) survival rate of animals 
at day 10 (Fig. 1D) we selected the 9th day as the endpoint of experiments. 
3.2. Analysing the effect of various synthetic I1-IR ligands on DSS-induced colonic 
inflammation 
Once-daily administration of I1-IR agonists moxonidine (0.01 - 1 mg/kg i.p., Figs. 2A-
2C) and rilmenidine (0.01 - 1 mg/kg i.p., Figs. 2D-2F) failed to influence the macroscopic signs 
(elevation of DAI, weight loss and colon shortening) of DSS-induced colitis. Similar results 
were obtained when animals were treated with the I1-IR antagonists AGN 192403 (0.1 - 10 
mg/kg i.p., Figs. 3A-3C) and efaroxan (0.1 - 1 mg/kg i.p., Figs. 3D-3F). Although in case of 
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AGN 192403 the lowest dose slightly decreased the DAI of DSS-treated mice at day 9 (Fig. 
3A), this effect was not dose-dependent. When injected to mice receiving normal tap water, 
none of the tested compounds affected the investigated parameters (Figs. 2-3). 
Qualitative histological analysis of distal colon samples confirmed the macroscopic 
findings. Compared to the histological picture of non-inflamed colons showing intact crypts 
and normal mucosal epithelial layer (Fig. 4A), treatment with 2.5 % DSS induced marked 
inflammation with epithelial destruction, loss of crypts, edematous submucosa, as well as 
mucosal and submucosal neutrophil infiltration (Fig. 4B), which was not influenced by any of 
the tested I1-IR ligands (Figs. 4C-4F). 
Similarly, as Fig. 5A demonstrates, the severe inflammation evoked by DSS was 
accompanied by remarkable (around 100-fold) elevation of MPO levels in the distal colon, 
indicating a massive infiltration of neutrophils into the tissue, but none of the I1-IR agonists and 
antagonists had any significant effect on it. Finally, serum samples from mice treated with 
saline, rilmenidine (0.1 mg/kg) or AGN 192403 (0.1 mg/kg) were analysed for their content of 
IL-6. The level of this pro-inflammatory cytokine was below the level of detection in control 
animals and raised upon DSS treatment, but remained unchanged in response to rilmenidine 
and AGN 192403 (Fig. 5B). 
3.3. Analysing the effect of endogenous IR ligands on DSS-induced colonic inflammation 
In the next step we analysed the effect of two endogenous IR ligands, agmatine (10 - 
100 mg/kg i.p.) and harmane (2.5 - 10 mg/kg per os), administered once daily. As Fig. 6 shows, 
we obtained similar results as with the synthetic compounds, i.e. they failed to significantly 
influence the development of DSS-induced colitis. Although in case of 30 mg/kg agmatine we 
recorded slightly lower DAI values at day 9 than in the DSS control group (Fig. 6A), this effect 
was not dose-dependent and agmatine did not affect any other inflammatory parameters (Figs. 
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6B-6C). Neither agmatine, nor harmane (or its vehicle) caused any effect in mice receiving 
normal tap water. 
3.4. Analysing the effect of twice-daily administered synthetic I1-IR ligands on DSS-
induced colonic inflammation 
We wondered whether the effect of I1-IR ligands on colitis can be enhanced by changing 
the treatment regimen and injecting them i.p., twice per day. As Fig. 7 demonstrates, DSS-
induced inflammation remained unchanged in response to rilmenidine (0.1 mg/kg), AGN 
192403 (0.1 mg/kg) and efaroxan (1 mg/kg). Likewise, moxonidine (0.1 mg/kg) failed to 
significantly influence the DSS-evoked elevation of DAI and colon shortening, but it slightly 
enhanced the weight loss of animals (Fig. 7B), which was not due to any effect on their daily 
food and water consumption (not shown). 
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4. Discussion 
This study demonstrates for the first time that I1-IR agonists moxonidine and 
rilmenidine, similarly to other synthetic and endogenous IR ligands, do not have a major 
influence on the inflammatory parameters of DSS-induced acute colitis in mice. Although our 
results suggest that imidazoline antihypertensives have neither significant beneficial, nor 
detrimental effect in patients with intestinal inflammation, the translational value of these 
findings needs to be verified with other experimental colitis models and human studies. 
Since the recognition and pharmacological characterization of non-adrenergic 
imidazoline binding sites a substantial effort has been put into understanding their functions 
and assessing their physiological importance. The I1-IR subtype, which displays high affinity 
for 2-aminoimidazolines such as clonidine, and medium affinity for imidazolines such as 
idazoxan (Dardonville and Rozas, 2004), has attracted particular attention due to its role in the 
regulation of cardiovascular functions (Bousquet et al. 1984, 2003). The concept that I1-IRs 
localized in the rostral ventrolateral medulla mediate or at least contribute to the hypotensive 
effect of clonidine and its structural analogs, whereas alpha2-adrenoceptors mediate the adverse 
effects (sedation, dry mouth) has led to the development of moxonidine and rilmenidine, which 
possess higher affinity for I1-IRs than for alpha2-adrenoceptors and used world-wide as 
antihypertensive agents (Bousquet et al. 2003; Edwards et al. 2012; Verbeuren et al. 1990). 
IRs are also localized throughout the GI tract; they were shown on parietal cells (Houi 
et al. 1987), stomach membranes (Molderings et al. 1995, 1998), gastric and intestinal smooth 
muscles (Tesson et al. 1992; Wikberg et al. 1991) as well as on colon epithelial cells (Senard et 
al. 1990). Hence, from the 90’s several studies have been conducted to assess the GI effects of 
imidazoline drugs and the contribution of IRs to these actions. Although the results are 
sometimes conflicting, the majority of studies indicate that IRs may mediate the stimulatory 
effect of imidazolines on gastric acid secretion (Glavin et al. 1995; Houi et al. 1987; Molderings 
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et al. 1999), whereas other receptors, mainly alpha2-adrenoceptors mediate their inhibitory 
effect on GI contractility and peristalsis (Colucci et al. 1998; Liu and Coupar 1997; Zádori et 
al. 2013). 
There is some direct and indirect evidence that moxonidine and rilmenidine, as well as 
other imidazoline drugs may have anti-inflammatory properties as well. Rilmenidine and 
clonidine were shown to reduce acute paw edema induced by carrageenan-, formalin-, serotonin 
or histamine in rats, an effect mediated most likely by alpha2-adrenoceptors (Gyires et al. 2009; 
Holsapple et al. 1984; Kulkarni et al. 1986). Moxonidine reduced systemic low-grade 
inflammation in hypertensive postmenopausal overweight women (Pöyhönen-Alho et al. 2008). 
Idazoxan and agmatine inhibited the expression of inducible nitric oxide synthase in vitro 
(Regunathan et al. 1999), although agmatine is also capable to interact with multiple other 
molecular targets, which can contribute to its cyto- and organoprotective effects (reviewed 
recently by Piletz et al. 2013). Furthermore, various novel imidazoline scaffolds were shown to 
inhibit human proteasome (Lansdell et al. 2013), which in turn prevented NF-κB mediated gene 
transcription in cell cultures (Sharma et al. 2004; Kahlon et al. 2009) and the production of pro-
inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in human 
blood (Kahlon et al. 2009). Although in the majority of these studies other molecular targets 
than IRs were found to mediate the anti-inflammatory action of imidazoline drugs, the 
intriguing hypothesis of Molderings et al. (2007a, b) that I1-IRs may belong to the family of 
S1P receptors and represent mixtures of homo and/or heterodimers of S1P1-3 receptors suggests 
that also pharmacological modulation of I1-IRs may result in reduced inflammation. Namely, it 
is well-established that S1P1-3 receptors are essential for immune cell trafficking and 
lymphocyte egress from lymphoid organs (Aoki et al. 2016), and S1P receptor modulators 
ameliorate the severity of inflammation in different diseases, including colitis (Daniel et al. 
2007; Deguchi et al. 2006; Snider et al. 2009). Therefore, it can be hypothesized that I1-IR 
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ligands may interfere with normal S1P signaling, which in turn might induce anti-inflammatory 
action. All the above data suggest that imidazoline drugs may have beneficial effects on gut 
inflammation, which could be exploited in the treatment of patients with IBD. 
On the other hand, it is well-established that many IR ligands, including moxonidine 
and rilmenidine, bind with nanomolar affinity to alpha2-adrenoceptors as well (Szabó 2002). 
Although some data suggest that activation of these receptors by clonidine improve the 
symptoms of patients with IBD (Furlan et al. 2006; Lechin et al. 1985), more recent evidence 
indicate that stimulation of alpha2-adrenoceptors may rather exacerbate colitis by inducing 
directly the release of various pro-inflammatory cytokines and chemokines from immune cells 
(Bai et al. 2009, 2015; Zádori et al. 2016). Moreover, their activation may inhibit the release of 
acetylcholine from cholinergic enteric nerves, which otherwise is anti-inflammatory by 
activating alpha7 nicotinic ACh receptors on macrophages (Wang et al. 2003). 
Thus, imidazoline drugs can potentially influence colitis in both way; either reduce the 
severity of inflammation and tissue damage by IR-dependent and/or -independent mechanisms, 
or exacerbate it by acting on alpha2-adrenoceptors. Either is the case, such an effect could be 
clinically relevant as well, and should be considered e.g. by the anti-hypertensive treatment of 
patients with coexisting IBD. Interestingly, to date no study has been conducted to analyse their 
effect on gut inflammation. 
In the present study we induced colitis by adding DSS to the drinking water of mice, 
which is one of the most commonly used model of intestinal inflammation (Perse and Cerar 
2012). Since we hypothesized that IR ligands may have primarily beneficial effect on colonic 
inflammation, we aimed at inducing moderate to severe colitis, yet with low rate of mortality, 
and established the appropriate DSS protocol first, in which mice received 2.5 % DSS for 7 
days and were sacrificed on day 9. With this protocol, DSS induced severe diarrhea, rectal 
bleeding and weight loss, which were accompanied by typical histopathological signs of 
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inflammation and tissue damage, significant reduction of colon length and elevation of MPO 
and IL-6 levels measured in the colon wall and serum, respectively. Mice were treated once 
daily with different IR ligands, such as moxonidine and rilmenidine (I1-IR agonists), AGN 
192403 (highly selective neutral antagonist (Mukaddam-Daher et al. 2006) or partial agonist 
(Zádori et al. 2014) of I1-IRs), efaroxan (I1-IR antagonist), as well as agmatine and harmane 
(endogenous IR agonists). All applied doses were selected based on literature data (see 
references in Section 2), and the dose range of moxonidine and rilmenidine was also clinically 
relevant (0.01 - 1 mg/kg, which corresponds approximately to 0.06 - 5.6 mg for a person 
weighing 70 kg) (Reagan-Show et al. 2007). 
By using the above-described DSS protocol and drug dosing regimen, none of the tested 
IR ligands influenced significantly the macroscopic and histological signs of DSS-induced 
inflammation. Likewise, the elevated colonic MPO content and serum IL-6 level remained 
unchanged in response to treatment with these drugs. 
Because plasma half-lives of the used I1-IR ligands are relatively short (e.g. 2 and 8 
hours in case of moxonidine and rilmenidine, respectively) (Edwards et al. 2012; Verbeuren et 
al. 1990), it might be argued that once daily administration of these agents is not enough to 
explore their potential anti- or pro-inflammatory actions. Although short plasma half-life does 
not necessarily mean short duration of action, for example, the antihypertensive action of both 
moxonidine and rilmenidine lasts 12-24 hours in humans (Edwards et al. 2012; Verbeuren et 
al. 1990), we changed the treatment regimen and injected them twice daily to test, whether it 
would enhance their potential intestinal effects. Rilmenidine, AGN 192403 and efaroxan still 
failed to influence the macroscopic signs of DSS-evoked colitis. Moxonidine had no effect on 
DAI values and colon shortening either, but it induced a slight weight loss, compared to the 
DSS control group. Because it did not affect the daily food and water consumption of mice, the 
wasting of animals may reflect a mild aggravation of disease severity. Since both moxonidine 
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and rilmenidine behave as agonists at alpha2-adrenoceptors and bind to them with comparable 
affinites (Eglen et al. 1998; Head and Mayorov 2006; Szabó 2002), but moxonidine is more 
potent at activating them (Zhu et al. 1999), it is possible that twice daily injection of 0.1 mg 
moxonidine to mice (which equals approximately to twice daily injection of the maximal 
recommended daily dose, 0.6 mg, in humans) (Farsang 2001) was capable to induce a slight, 
alpha2-adrenoceptor-mediated exacerbation of colonic inflammation. 
In summary, from our study the following conclusions can be drawn. 1) I1-IRs do not 
influence the severity of acute experimental colitis induced by DSS in the mouse. 2) Although 
IR ligands might induce anti-inflammatory effects in certain models and diseases, by acting on 
I1-IRs or other molecular targets, this is probably not sufficient to alleviate inflammation of the 
gut. 3) IR ligands, though bind also to alpha2-adrenoceptors, which may mediate a pro-
inflammatory action, failed to aggravate significantly DSS-colitis. Hence, these results may 
suggest that imidazoline antihypertensives have neither significant beneficial, nor detrimental 
effect in patients with IBD. 
However, it should be emphasized that IR ligands have been tested only in one of the 
numerous animal models of IBD, and only in the acute phase of inflammation. To date more 
than 60 different colitis models have been developed, which differ in several aspects, such as 
pathomechanism, clinical/histological picture and cytokine profile (Hoffmann et al. 2002; 
Mizoguchi 2012; Wirtz and Neurath 2007). Consquently, a drug maybe effective in one, but 
ineffective in other model of intestinal inflammation depending on its mechanism of action 
(Park et al. 2004). Moreover, although DSS-induced colitis is one of the most widely used IBD 
models, due to the convenient induction, defined onset of intestinal inflammation, and its 
relevance for the translation of animal data to human IBD (Melgar et al. 2008), even the 
clinically widely used, effective drugs, such as olsalazine, budesonide or methotrexate have had 
variable positive effects in this model, depending on several factors (concentration of DSS and 
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duration of exposure, route of drug administration, genetic background of animals, etc.) (see 
e.g. Loher et al. 2003; Melgar et al. 2008; Sann et al. 2013). Therefore, although our study 
strongly suggests that imidazoline drugs do not have a major impact on intestinal inflammation, 
the translational value of these findings needs to be verified by other experimental colitis 
models (e.g. by using other chemical inducers or transgenic mice prone to develop colitis) and 
also by clinical studies. 
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Figure legends 
Fig. 1. Characterization of the effect of 2.5 % dextran sulfate sodium (DSS) by using different 
protocols. DSS was applied for 3 different time intervals (3, 5 and 7 days), control animals 
drank normal tap water. Animals receiving DSS for 3 days (n=6) and for 5 days (n=12), as well 
as control animals (n=12) were sacrificed on day 10, whereas animals receiving DSS for 7 days 
(n=18) were sacrificed at 3 different time points (6-6 mice on days 7, 9 and 10). The severity 
of colitis was assessed by determining the disease activity index (DAI) (A), weight loss (B), 
reduction of colon length (C) and survival rate (D). The values represent means ± SEM. *p<0.05 
vs control group, for statistical analysis Friedman test (panel A), two-way repeated measures 
ANOVA (panel B) and one-way ANOVA (panel C) were used, followed by Holm-Sidak post 
hoc test. Kaplan-Meier test was used for analysis of survival rates (panel D). 
Fig. 2. The effect of moxonidine (MOX, 0.01 - 1 mg/kg, panels A-C) and rilmenidine (RIL, 
0.01 - 1 mg/kg, panels D-F) on the macroscopic signs of DSS-induced colitis. Drugs or saline 
(SAL) were injected intraperitoneally (i.p.), once daily. Neither moxonidine, nor rilmenidine 
influenced significantly the DSS-evoked elevation of disease activity index (DAI), weight loss 
or colon shortening. The values represent means ± SEM (n=6/group). *p<0.05 vs SAL. For 
statistical analysis Friedman test (panels A, D), two-way repeated measures ANOVA (panels 
B, E) and one-way ANOVA (panels C, F) were used, followed by Holm-Sidak post hoc test. 
Fig. 3. The effect of AGN 192403 (AGN, 0.1 - 10 mg/kg, panels A-C) and efaroxan (EFA, 0.1 
- 1 mg/kg, panels D-F) on the macroscopic signs of DSS-induced colitis. Drugs or saline (SAL) 
were injected intraperitoneally (i.p.), once daily. Neither AGN 192403, nor efaroxan had major 
impact on DSS-evoked elevation of disease activity index (DAI), weight loss or colon 
shortening. The values represent means ± SEM (n=6/group). *p<0.05 vs SAL, +p<0.05 vs 
DSS+SAL. For statistical analysis Friedman test (panels A, D), two-way repeated measures 
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ANOVA (panels B, E) and one-way ANOVA (panels C, F) were used, followed by Holm-Sidak 
post hoc test. 
Fig. 4. Representative histological micrographs of colonic tissue sections, haematoxylin-eosin 
staining. Full-thickness pieces of the distal colon were obtained from mice treated with saline 
i.p. + normal tap water (A), saline i.p. + 2.5 % DSS (B), moxonidine 0.1 mg/kg i.p. + 2.5 % 
DSS (C), rilmenidine 0.1 mg/kg i.p. + 2.5 % DSS (D), AGN 192403 0.1 mg/kg i.p. + 2.5 % 
DSS (E) or efaroxan 1 mg/kg i.p. + 2.5 % DSS (F). Histological signs of severe inflammation 
were observed in all DSS-treated groups, irrespectively of whether they were treated with I1-IR 
ligands or not. Arrow shows intact crypts in control group, whereas asterisks show massive 
mucosal and submucosal neutrophil infiltration in DSS-treated groups. Scalebar: 200 µm. 
Fig. 5. The effect of synthetic I1-IR agonists and antagonists on DSS-induced elevation of 
colonic myeloperoxidase (MPO) and serum interleukin-6 (IL-6) levels. Panel A: Moxonidine 
(MOX, 0.1 mg/kg), rilmenidine (RIL, 0.01 - 1 mg/kg), AGN 192403 (AGN, 0.1 - 10 mg/kg) 
and efaroxan (EFA, 1 mg/kg) all failed to significantly influence the DSS-evoked elevation of 
MPO level in the colon wall. The values represent means ± SEM (DSS+SAL group: n=13, all 
other groups: n=6). *p<0.05 vs SAL, one-way ANOVA, followed by Holm-Sidak post hoc test. 
Panel B: Rilmenidine (RIL, 0.1 mg/kg) and AGN 192403 (AGN, 0.1 mg/kg) did not influence 
the serum IL-6 content of mice, compared to DSS+SAL group. The values represent means ± 
SEM (n=5/group). One-way ANOVA, followed by Holm-Sidak post hoc test was used for 
statistical analysis between DSS-treated groups. Serum IL-6 level in the control group (saline 
i.p. + tap water) was below the level of detection limit (ND, not detectable). 
Fig. 6. The effect of agmatine (AGM, 10 - 100 mg/kg, panels A-C) and harmane (HAR, 2.5 - 
10 mg/kg, panels D-F) on the macroscopic signs of DSS-induced colitis. Agmatine and saline 
(SAL) were injected i.p., whereas harmane and its vehicle (VEH), 1.7 % acetic acid were 
injected intragastrically by an oral gavage, once daily. Neither agmatine, nor harmane had major 
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effect on DSS-evoked elevation of disease activity index (DAI), weight loss or colon 
shortening. The values represent means ± SEM (n=6/group). *p<0.05 vs SAL, +p<0.05 vs 
DSS+SAL. For statistical analysis Friedman test (panels A, D), two-way repeated measures 
ANOVA (panels B, E) and one-way ANOVA (panels C, F) were used, followed by Holm-Sidak 
post hoc test. 
Fig. 7. The effect of twice-daily administered synthetic I1-IR agonists and antagonists on the 
macroscopic signs of DSS-induced colitis. Moxonidine (MOX, 0.1 mg/kg), rilmenidine (RIL, 
0.1 mg/kg), AGN 192403 (AGN, 0.1 mg/kg) and efaroxan (EFA, 1 mg/kg), as well as saline 
(SAL) were injected i.p. Moxonidine slightly aggravated the DSS-induced weight loss, whereas 
the other drugs failed to affect the DSS-induced elevation of disease activity index (DAI) (A), 
weight loss (B) or colon shortening (C). The values represent means ± SEM (n=6/group). 
*p<0.05 vs SAL, +p<0.05 vs DSS+SAL. For statistical analysis Friedman test (panel A), two-
way repeated measures ANOVA (panel B) and one-way ANOVA (panel C) were used, 
followed by Holm-Sidak post hoc test. 
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Table 1. Chemical names of tested IR ligands and their affinity constants (pKi) in 
various cells and tissues for I1- and I2-IRs, and to alpha2-adrenoceptors (alpha2-AR) 
 
Drug Chemical name I1-IR 
(pKi) 
I2-IR 
(pKi) 
alpha2-AR 
(pKi) 
Moxonidine 4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-
6-methoxy-2-methyl-5-pyrimidinamine 
8.37a <5a 7.11a 
Rilmenidine 2-[N-(Dicyclopropylmethyl)amino] 
oxazoline 
7.22a 5.96a 6.90a 
AGN 192403 (±)-2-endo-Amino-3-exo-isopropylbicyclo 
[2.2.1] heptane 
7.38b NDb <5b 
Efaroxan 2-ethyl-2-(imidazolin-2-yl)-2,3-
dihydrobenzofuran 
7.28a <5a 5.74-7.87a 
Agmatine (4-Aminobutyl)guanidine 7.48a <5a <5a 
Harmane 1-Methyl-9H-pyrido[3,4-b]indole 7.51c 7.31c <5c 
Ki values were taken from the following references: aEglen et al. 1998; bMunk et al. 
1996; cHusbands et al. 2001. (Affinity values, however, can vary substantially in different 
species and tissues.) Affinites for non-I1-non-I2-IRs are in most cases lacking, and are not 
included in the table. 
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